Abstracts tagged "Mannose binding lectin (MBL)"

Abstract Number: 718 • 2015 ACR/ARHP Annual Meeting
Urinary MBL : A Promising Biomarker for Predicting Flare in Lupus Nephritis
Sarit sekhar Pattanaik¹, Madhukara HM¹, Aditya kumar Panda², Rashmi ranjan Sahoo¹, Rina Tripathy³ and Bidyut kumar Das¹, ¹Medicine, SCB Medical College, Cuttack, India, ²Centre for Life science, Central University of Jharkand, Ranchi, India, ³Biochemistry, SCB Medical College, Cuttack, India
Background/Purpose: Nephritis is the most common cause of mortality and morbidity in SLE, develops in 40 to 70% of cases in 5-10 years with 60%…
Abstract Number: 1705 • 2014 ACR/ARHP Annual Meeting
The Lectin Pathway of Complement – a Potential Role in the Pathogenesis and Disease Manifestations of Systemic Sclerosis
Michael Osthoff^1,2, Gene-Siew Ngian^2,3,4, Melinda Dean⁵, Mandana Nikpour⁶, Wendy Stevens⁷, Susanna Proudman⁸, Damon Eisen¹ and Joanne Sahhar^3,9, ¹Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Australia, ²Department of Medicine, The University of Melbourne, Melbourne, Australia, ³Department of Rheumatology, Monash Medical Centre, Clayton, Australia, ⁴Department of Rheumatology, Royal Melbourne Hospital, Parkville, Australia, ⁵Research and Development, Australian Red Cross Blood Service, Brisbane, Australia, ⁶Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia, ⁷Department of Rheumatology, St. Vincent’s Hospital, Fitzroy, Australia, ⁸Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁹Monash Health, Melbourne, Australia
Background/Purpose: Repetitive episodes of ischemia and reperfusion (I/R) are a cardinal feature of the pathogenesis of systemic sclerosis (SSc), which precedes tissue fibrosis. The complement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].